Imaging of Protein Synthesis: in Vitro and in Vivo Evaluation of (44)Sc-DOTA-puromycin

Overview

Journal Mol Imaging Biol

Publisher Springer

Specialties Molecular Biology
Radiology

Date 2012 May 9

PMID 22565849

Citations 11

Authors

Sebastian Eigner

Denis R Beckford Vera

Marco Fellner

Natalia S Loktionova

Markus Piel

Ondrej Lebeda

Frank Rosch

Tobias L Ross

Katerina Eigner Henke

Affiliations

Soon will be listed here.

Abstract

Purpose: The purpose of this study was to investigate whether (44)Sc-labeled puromycin can be utilized for imaging of protein synthesis in vivo.

Methods: For micro-positron emission tomographic (μPET) studies, 20-25 MBq of [(44)Sc]-DOTA-puromycin was administered to tumor-bearing rats, and animals were scanned for 1 h dynamically. Results were further validated by dissecting organs and tissues of the animals after the measurement and in vitro blocking experiments using puromycin or cycloheximide to block protein synthesis.

Results: μPET images of tumor-bearing rats showed significant tumor uptake of [(44)Sc]-DOTA-puromycin and a clear-cut tumor visualization. In both blocking experiments, cellular uptake of [(44)Sc]-DOTA-puromycin ([(44)Sc]-DOTA-Pur) could be suppressed by blocking protein synthesis.

Conclusions: We report for the first time successful μPET imaging with (44)Sc obtained from a (44)Ti/(44)Sc generator, as well as noninvasive μPET imaging of ribosomal activity, respectively protein synthesis, with a puromycin-based radiopharmaceutical and the direct correlation between cellular uptake of [(44)Sc]-DOTA-Pur and protein synthesis.

Citing Articles

Current State of Ti/Sc Radionuclide Generator Systems and Separation Chemistry.

Schmidt C, Gajecki L, Deri M, Sanders V Curr Radiopharm. 2022; 16(2):95-106.

PMID: 36372922 PMC: 10375575. DOI: 10.2174/1874471016666221111154424.

Exploring the Application of Bifunctional Metal Chelators in Treating Triple-Negative Breast Cancer.

Li K, Zhang Y, Wang X, Zhu R, Ma C, Hu R Front Bioeng Biotechnol. 2021; 9:697862.

PMID: 34414172 PMC: 8369237. DOI: 10.3389/fbioe.2021.697862.

Production of scandium radionuclides for theranostic applications: towards standardization of quality requirements.

Mikolajczak R, Huclier-Markai S, Alliot C, Haddad F, Szikra D, Forgacs V EJNMMI Radiopharm Chem. 2021; 6(1):19.

PMID: 34036449 PMC: 8149571. DOI: 10.1186/s41181-021-00131-2.

The science of puromycin: From studies of ribosome function to applications in biotechnology.

Aviner R Comput Struct Biotechnol J. 2020; 18:1074-1083.

PMID: 32435426 PMC: 7229235. DOI: 10.1016/j.csbj.2020.04.014.

Image quality analysis of Sc on two preclinical PET scanners: a comparison to Ga.

Rosar F, Buchholz H, Michels S, Hoffmann M, Piel M, Waldmann C EJNMMI Phys. 2020; 7(1):16.

PMID: 32166581 PMC: 7067939. DOI: 10.1186/s40658-020-0286-3.

References

Haubner R . PET radiopharmaceuticals in radiation treatment planning - synthesis and biological characteristics. Radiother Oncol. 2010; 96(3):280-7. DOI: 10.1016/j.radonc.2010.07.022. View

Meyer G, Macke H, Schuhmacher J, Knapp W, Hofmann M . 68Ga-labelled DOTA-derivatised peptide ligands. Eur J Nucl Med Mol Imaging. 2004; 31(8):1097-104. DOI: 10.1007/s00259-004-1486-0. View

Smith-Jones P, Stolz B, Bruns C, Albert R, Reist H, Fridrich R . Gallium-67/gallium-68-[DFO]-octreotide--a potential radiopharmaceutical for PET imaging of somatostatin receptor-positive tumors: synthesis and radiolabeling in vitro and preliminary in vivo studies. J Nucl Med. 1994; 35(2):317-25. View

Nemoto N, Yanagawa H . Fluorescence labeling of the C-terminus of proteins with a puromycin analogue in cell-free translation systems. FEBS Lett. 1999; 462(1-2):43-6. DOI: 10.1016/s0014-5793(99)01474-x. View

Roivainen A, Tolvanen T, Salomaki S, Lendvai G, Velikyan I, Numminen P . 68Ga-labeled oligonucleotides for in vivo imaging with PET. J Nucl Med. 2004; 45(2):347-55. View

Jager P, de Korte M, Lub-de Hooge M, van Waarde A, Koopmans K, Perik P . Molecular imaging: what can be used today. Cancer Imaging. 2005; 5 Spec No A:S27-32. PMC: 1665304. DOI: 10.1102/1470-7330.2005.0023. View

Yarmolinsky M, Haba G . INHIBITION BY PUROMYCIN OF AMINO ACID INCORPORATION INTO PROTEIN. Proc Natl Acad Sci U S A. 1959; 45(12):1721-9. PMC: 222790. DOI: 10.1073/pnas.45.12.1721. View

Pruszynski M, Loktionova N, Filosofov D, Rosch F . Post-elution processing of (44)Ti/(44)Sc generator-derived (44)Sc for clinical application. Appl Radiat Isot. 2010; 68(9):1636-41. DOI: 10.1016/j.apradiso.2010.04.003. View

Starck S, Roberts R . Puromycin oligonucleotides reveal steric restrictions for ribosome entry and multiple modes of translation inhibition. RNA. 2002; 8(7):890-903. PMC: 1370306. DOI: 10.1017/s1355838202022069. View

10.

Nathans D . PUROMYCIN INHIBITION OF PROTEIN SYNTHESIS: INCORPORATION OF PUROMYCIN INTO PEPTIDE CHAINS. Proc Natl Acad Sci U S A. 1964; 51:585-92. PMC: 300121. DOI: 10.1073/pnas.51.4.585. View

11.

Nemoto N, Kobayashi K, Yanagawa H . Specific bonding of puromycin to full-length protein at the C-terminus. Nucleic Acids Res. 2000; 28(5):1176-82. PMC: 102619. DOI: 10.1093/nar/28.5.1176. View

12.

Foss C, Mease R, Fan H, Wang Y, Ravert H, Dannals R . Radiolabeled small-molecule ligands for prostate-specific membrane antigen: in vivo imaging in experimental models of prostate cancer. Clin Cancer Res. 2005; 11(11):4022-8. DOI: 10.1158/1078-0432.CCR-04-2690. View